|
1.
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Chen WQ, Wang QS, Zhang SW, et al: An
analysis of incidence and mortality of pancreas cancer in China
2003–2007. China Cancer. 21:248–253. 2012.
|
|
3.
|
Siegel R, Naishadham D and Jemal A: Cancer
Statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
4.
|
Cartwright T, Richards DA and Boehm KA:
Cancer of the pancreas: are we making progress? A review of studies
in the US Oncology Research Network. Cancer Control. 15:308–313.
2008.PubMed/NCBI
|
|
5.
|
Wan X, Mendoza A, Khanna C and Helman LJ:
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine
model of osteosarcoma. Cancer Res. 65:2406–2411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Diakowski W, Grzybek M and Sikorski AF:
Protein 4.1, a component of the erythrocyte membrane skeleton and
its related homologue proteins forming the protein 4.1/FERM
superfamily. Folia Histochem Cytobiol. 44:231–248. 2006.PubMed/NCBI
|
|
7.
|
Wakayama T, Nakata H, Kurobo M, et al:
Expression, localization, and binding activity of the
ezrin/radixin/moesin proteins in the mouse testis. J Histochem
Cytochem. 57:351–362. 2009. View Article : Google Scholar
|
|
8.
|
Arpin M, Chirivino D, Naba A and
Zwaenepoel I: Emerging role for ERM proteins in cell adhesion and
migration. Cell Adh Migr. 5:199–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Jörgren F, Nilbert M, Rambech E, et al:
Ezrin expression in rectal cancer predicts time to development of
local recurrence. Int J Colorectal Dis. 27:893–899. 2012.PubMed/NCBI
|
|
10.
|
Arslan AA, Silvera D, Arju R, et al:
Atypical ezrin localization as a marker of locally advanced breast
cancer. Breast Cancer Res Treat. 134:981–988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Evans DG, Ramsden RT, Shenton A, et al:
What are the implications in individuals with unilateral vestibular
schwannoma and other neurogenic tumors? J Neurosurg. 108:92–96.
2008. View Article : Google Scholar
|
|
12.
|
Tsukita S, Yonemura S and Tsukita S: ERM
proteins: head-to-tail regulation of actin-plasma membrane
interaction. Trends Biochem Sci. 22:53–58. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ye K: Phosphorylation of merlin regulates
its stability and tumor suppressive activity. Cell Adh Migr.
1:196–198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Muranen T, Grönholm M, Lampin A, et al:
The tumor suppressor merlin interacts with microtubules and
modulates Schwann cell microtubule cytoskeleton. Hum Mol Genet.
16:1742–1751. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kissil JL, Wilker EW, Johnson KC, et al:
Merlin, the product of the Nf2 tumor suppressor gene, is an
inhibitor of the p21-activated kinase, Pak1. Mol Cell. 12:841–849.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Alfthan K, Heiska L, Grönholm M, et al:
Cyclic AMP-dependent protein kinase phosphorylates merlin at serine
518 independently of p21-activated kinase and promotes merlin-ezrin
heterodimerization. J Biol Chem. 279:18559–18566. 2004. View Article : Google Scholar
|
|
17.
|
Jin H, Sperka T, Herrlich P and Morrison
H: Tumorigenic transformation by CPI-17 through inhibition of a
merlin phosphatase. Nature. 442:576–579. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Bruce B, Khanna G, Ren L, et al:
Expression of the cytoskeleton linker protein ezrin in human
cancers. Clin Exp Metastasis. 24:69–78. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Hunter KW: Ezrin, a key component in tumor
metastasis. Trends Mol Med. 10:201–204. 2004. View Article : Google Scholar
|
|
20.
|
Yu Y, Khan J, Khanna C, et al: Expression
profiling identifies the cytoskeletal organizer ezrin and the
developmental homeoprotein Six 1 as keymetastatic regulators. Nat
Med. 10:175–181. 2004. View
Article : Google Scholar
|
|
21.
|
Ohtani K, Sakamoto H, Rutherford T, et al:
Ezrin, a membrane-cytoskeletal linking protein, is involved in the
process of invasion of endometrial cancer cells. Cancer Lett.
147:31–38. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Hiscox S and Jiang WG: Ezrin regulates
cell-cell and cell-matrix adhesion, a possible role with
E-cadherin/beta-catenin. Cell Sci. 112:3081–3090. 1999.PubMed/NCBI
|
|
23.
|
Ren L, Hong SH, Cassavaugh J, et al: The
actin-cytoskeleton linker protein ezrin is regulated during
osteosarcoma metastasis by PKC. Oncogene. 28:792–802. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Wittekind C and Oberschmid B: TNM
classification of malignant tumors 2010: General aspects and
amendments in the general section. Pathologe. 31:333–338. 2010.(In
German).
|
|
25.
|
Cui Y, Li T, Zhang D and Han J: Expression
of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal
adenocarcinoma. Cancer Invest. 28:242–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Mathew J, Hines JE, Obafunwa JO, et al:
CD44 is expressed in hepatocellular carcinomas showing vascular
invasion. J Pathol. 179:74–79. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Moilanen J, Lassus H, Leminen A, et al:
Ezrin immumoreactivity in relation to survival in serous ovarian
carcinoma patients. Gynecol Oncol. 90:273–281. 2003. View Article : Google Scholar : PubMed/NCBI
|
